Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

Osteoporosis International

Volumn 22, Issue 10, 2011, Pages 2709-2719

  Fahrleitner Pammer, A ^a   Langdahl, B L ^b   Marin, F ^c   Jakob, F ^d   Karras, D ^e   Barrett, A ^c   Ljunggren, O ^f   Walsh, J B ^g   Rajzbaum, G ^h   Barker, C ^c   Lems, W F ⁱ  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

^c ELI LILLY AND COMPANY   (United States)

^d UNIVERSITY OF WÜRZBURG   (Germany)

^e Veterans Administration Hospital   (Greece)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^g TRINITY COLLEGE DUBLIN   (Ireland)

^h SAINT JOSEPH HOSPITAL   (France)

ⁱ VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Back pain; Fracture; Osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; CALCITONIN; CALCIUM; PARATHYROID HORMONE[1-34]; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

ARTICLE; BACKACHE; DRUG WITHDRAWAL; FEMALE; HIP FRACTURE; HUMAN; HUMERUS FRACTURE; LEG FRACTURE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUESTIONNAIRE; RIB FRACTURE; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VISUAL ANALOG SCALE;

ACTIVITIES OF DAILY LIVING; AGED; BACK PAIN; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FOLLOW-UP STUDIES; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PAIN MEASUREMENT; QUALITY OF LIFE; SPINAL FRACTURES; TERIPARATIDE; TREATMENT OUTCOME;

EID: 80054069511     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1498-5     Document Type: Article

References (35)

1. Cockerill W, Lunt M, Silman AJ, Cooper C, Lips P, Bhalla AK, Cannata JB, Eastell R, Felsenberg D, Gennari C, Johnell O, Kanis JA, Kiss C, Masaryk P, Naves M, Poor G, Raspe H, Reid DM, Reeve J, Stepan J, Todd C, Woolf AD, O'Neill TW (2004) Healthrelated quality of life and radiographic vertebral fracture. Osteoporos Int 15:113-119
2. Cooper C, Jakob F, Chinn C, Martin-Mola E, Fardellone P, Adami S, Thalassinos NC, Melo-Gomes J, Torgerson D, Gibson A, Marin F (2008) Fracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO). Osteoporos Int 19:493-501
3. Francis RM, Aspray TJ, Hide G, Sutcliffe AM, Wilkinson P (2008) Back pain in osteoporotic vertebral fractures. Osteoporos Int 19:895-903
4. Gold DT (1996) The clinical impact of vertebral fractures: quality of life in women with osteoporosis. Bone 18(Suppl 3):185-189
5. Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726-1733
6. Oleksik A, Lips P, Dawson A, Minshall ME, Shen W, Cooper C, Kanis J (2000) Health-related quality of life in postmenopausal women with low BMD with or without prevalent fractures. J Bone Miner Res 15:1384-1392
7. Salaffi F, Cimmino MA, Malavolta N, Carotti M, Di Matteo L, Scendoni P, Grassi W, Italian Multicentre Osteoporotic Fracture Study Group (2007) The burden of prevalent fractures on healthrelated quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 34:1551-1560
8. Silverman SL, Minshall ME, Shen W, Harper KD, Xie S (2001) The relationship of health-related quality of life to prevalent and incident vertebral fractures in postmenopausal women with osteoporosis: results from the Multiple Outcomes of Raloxifene Evaluation Study. Arthritis Rheum 44:2611-2619
9. Silverman SL, Piziak VK, Chen P, Misurski DA, Wagman RB (2005) Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis. J Rheumatol 32:2405-2409
10. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556-561
11. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster J-Y, Borgstrom F, Rizzoli R, on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) (2008) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 19:399-428
12. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434-1441
13. Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinarypatients. Osteoporos Int 11:533-536
14. Silverman SL (2009) From randomized controlled trials to observational studies. Am J Med 122:114-120
15. Langdahl BL, Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Fahrleitner-Pammer A, Walsh JB, Barker C, Kutahov A, Marin F (2009) Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 85:484-493
16. Rajzbaum G, Jakob F, Karras D, Ljunggren O, Lems WF, Langdahl BL, Fahrleitner-Pammer A, Walsh JB, Gibson A, Tynan AJ, Marin F (2007) Characterization of patients in the European Forsteo Observational Study (EFOS): postmenopausal women entering teriparatide treatment in a community setting. Curr Med Res Opin 24:377-384
17. Ross PD (1997) Clinical consequences of vertebral fractures. Am J Med 103:30S-42S
18. Sriwatanakul K, Kelvie W, Lasagna L, Calimlim JF, Weis OF, Mehta G (1983) Studies with different types of visual analog scales for measurement of pain. Clin Pharmacol Ther 34:234-239
19. Laing YY, Zeger SL (1986) Longitudinal data analysis using generalised linear models. Biometrika 73:13-22
20. Hosmer DW Jr, Lemershow S (2000) Applied logistic regression, 2nd edn. Wiley, New York
21. Adami S, San Martin J, Muñoz-Torres M, Econs MJ, Xie L, Dalsky GP, McClung M, Felsenberg D, Brown JP, Brandi ML, Sipos A (2008) Effect of raloxifene after recombinant teriparatide [hPTH (1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int 19:87-94
22. Eastell R, Nickelsen T, Marin F, Barker C, Hadji P, Farrerons J, Audran M, Boonen S, Brixen K, Melo Gomes J, Obermayer-Pietsch B, Avramidis A, Sigurdsson G, Gluer CC (2009) Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res 24:726-736
23. Lindsay R, Scheele WH, Neer R, Pohl G, Adami S, Mautalen C, Reginster J-Y, Stepan JJ, Myers SL, Mitlak BH (2004) Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med 164:2024-2030
24. Prince R, Sipos A, Hossain A, Syversen U, Ish-Shalom S, Marcinowska E, Halse J, Lindsay R, Dalsky GP, Mitlak BH (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507-1513
25. Nevitt MC, Chen P, Dore RK, Reginster JY, Kiel DP, Zanchetta JR, Glass EV, Krege JH (2006) Reduced risk of back pain following teriparatide treatment: a meta-analysis. Osteoporos Int 17:273-280
26. Nevitt MC, Chen P, Kiel DP, Reginster JY, Dore RK, Zanchetta JR, Glass EV, Krege JH (2006) Reduction in the risk of developing back pain persists at least 30 months after discontinuation of teriparatide treatment: a meta-analysis. Osteoporos Int 17:1630-1637
27. Buchbinder R, Osborne RH, Ebeling PR, Wark JD, Mitchell P, Wriedt C, Graves S, Staples MP, Murphy B (2009) A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures. N Engl J Med 361:557-568
28. Kallmes DF, Comstock BA, Heagerty PJ, Turner JA, Wilson DJ, Diamond TH, Edwards R, Gray LA, Stout L, Owen S, Hollingworth W, Ghdoke B, Annesley-Williams DJ, Ralston SH, Jarvik JG (2009) A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med 361:569-579
29. Nevitt MC, Thompson DE, Black DM, Rubin SR, Ensrud K, Yates AJ, Cummings SR, for the Fracture Intervention Trial Research Group (2000) Effect of alendronate on limited-activity days and beddisability days caused by back pain in postmenopausal women with existing vertebral fractures. Arch Intern Med 160:77-85
30. Iwamoto J, Takeda T, Sato Y, Uzawa M (2004) Effects of alendronate on metacarpal and lumbar bone mineral density, bone resorption and chronic back pain in postmenopausal women with osteoporosis. Clin Rheumatol 23:383-389
31. Miller PD, Shergy WJ, Body J-J, Chen P, Rohe ME, Krege JH (2005) Long-term reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate. J Rheumatol 32:1556-1562
32. Knopp JA, Diner BM, Blitz M, Lyritis GP, Rowe BH (2005) Calcitonin for treating acute pain of osteoporotic vertebral compression fractures: a systematic review of randomized, controlled trials. Osteoporos Int 16:1281-1290
33. Papadokstakis G, Katonis P, Damilakis J, Hadjipavlou A (2005) Does raloxifene treatment influence back pain and disability among postmenopausal women with osteoporosis? Eur Spine J 14:977-981
34. Papadokostakis G, Damilakis J, Mantzouranis E, Katonis P, Hadjipavlou A (2006) The effectiveness of calcitonin on chronic back pain and daily activities in postmenopausal women with osteoporosis. Eur Spine J 15:356-362
35. Scharla S, Oertel H, Helsberg K, Kessler F, Langer F, Nickelsen T (2006) Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration. Curr Med Res Opin 22:2393-2402